BiotechTube
TheraVida

TheraVida

San Diego, United States· Est.
theravida.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

TheraVida is a private, clinical-stage biopharmaceutical company developing Anhydrix™, a proprietary oral combination drug for the treatment of hyperhidrosis. The company's core technology pairs an agonist with an antagonist in a unique formulation aimed at reducing side effects while maintaining efficacy. Following a successful Phase 2 trial, TheraVida has licensed Anhydrix™ to Dermavant Sciences for worldwide development, positioning the company as a pipeline-focused entity with a partnered asset.

Hyperhidrosis

Technology Platform

Proprietary combination drug technology pairing an agonist with a delayed-onset, immediate-release profile and an antagonist to reduce side effects.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The large, underserved hyperhidrosis market lacks well-tolerated systemic oral therapies, creating a significant opportunity for Anhydrix™.
The partnership with Dermavant Sciences provides expertise and resources for global development and commercialization.
The core combination technology could potentially be applied to other conditions where side effect mitigation is a key challenge.

Risk Factors

The company's value is concentrated in a single, partnered asset, creating high binary risk dependent on a partner's execution.
The competitive landscape for hyperhidrosis includes established procedural and pharmaceutical options.
The novel combination approach may not demonstrate sufficient superiority in larger, pivotal trials to gain regulatory approval or market share.

Competitive Landscape

Hyperhidrosis treatment competition includes topical aluminum salts (OTC), botulinum toxin injections (Botox), iontophoresis devices, and off-label oral anticholinergics like glycopyrrolate. TheraVida's Anhydrix™ aims to compete directly in the systemic oral segment by offering an improved tolerability profile. Other biopharma companies may also be developing novel systemic or topical agents for this condition.

More companies in Small Molecule Drugs →More companies in United States →